Clinical trials: Impulsive Aggression
Anxiety, Depression Disorder
Screening and Monitoring of Mental Health in Educational Settings: Programme for Detection, Psychoeducation and Self-help
Adolescence is a critical developmental stage during which many mental health problems first emerge. However, a large proportion of these issues go undetected and untreated.
- Conditions
- Anxiety, Depression Disorder, Bullying, Addiction
- Trial name
- SENSE (NCT07818603)
- Testing
- program for the detection, referral, and psychoeducation in adolescents
- Where
- Spain
- Volunteers
- 436 people, healthy volunteers welcome
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Impulsive Aggression Comorbid With ADHD
A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
This will be a randomized, double-blind, placebo-controlled, dose-ranging, efficacy and safety study in children with impulsive aggression comorbid with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01364662
- Testing
- SPN-810
- Where
- 27 sites in United States
- Volunteers
- 121 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Mental Health Issue
The Relationship Between Internet-use Behavior and Mental Health in Youth
Introduction: WHO defines youth as 15-24 years age group. At this stage, the brain is still under development, with high impulsiveness, being fond of stimulation and yearning for peer life.
- Trial name
- NCT06284551
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of Impulsive Aggression (IA) in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with…
- Trial name
- NCT02618408
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 28 sites in United States
- Volunteers
- 333 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Impulsive Aggression, ADHD
Dialectical Behavioral Therapy Skills for Impulsive Aggression
This trial aims to Study the efficacy of DBT skills for impulsive aggression and executive dysfunctions in drug naïve children who are presented with impulsive aggression and ADHD and attending Child and adolescent clinic at…
- Conditions
- Impulsive Aggression, ADHD, Executive Dysfunction
- Trial name
- NCT05351944
- Testing
- Dialectical behavioral therapy skills for the intervention experimental group A, psychoeducation or Atomoxetine or stimulants according to ADHD severity
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Alexandria University
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study were invited to participate in this study.
- Trial name
- NCT02691182
- Testing
- SPN-810
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Conduct Disorder
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior.
- Trial name
- NCT00154362
- Testing
- Oxcarbazepine
- Volunteers
- 50 people
- Sponsor
- Novartis
Attention Deficit Hyperactivity Disorder
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
The purpose of this study was to evaluate the effect of SPN-810 for the treatment of impulsive aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard ADHD treatment.
- Trial name
- NCT03597503
- Testing
- SPN-810
- Where
- 38 sites in United States
- Volunteers
- 41 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Video Game Addiction, Gaming Disorder
Community-Based Intervention to Reduce Problematic Video Game Use in First-Year Secondary School Students: A Cluster Randomised Controlled Trial
This cluster randomised controlled trial will evaluate whether a community-based, multicomponent intervention can reduce problematic video game use and gaming disorder among first-year secondary school students in Pontevedra…
- Trial name
- AQJ (NCT07357792)
- Testing
- Community-Based Component, Adolescent Mindfulness Component, Adult Mindfulness Component
- Where
- Spain
- Volunteers
- 492 people, healthy volunteers welcome
- Sponsor
- Fundacin Biomedica Galicia Sur
Impulsive Aggression Comorbid With ADHD in Children
Open-Label, Extension Study to 810P202
Open-label, extension study for subjects that completed 810P202 to examine long term safety and tolerability of repeated dosing of SPN-810M as an adjunctive therapy in children with Impulsive Aggression Comorbid with…
- Trial name
- NCT01416064
- Testing
- Molindone
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Aggression, Hyperactivity
Infant Psychiatry Home Visitation Program
This is a proposed home visitation program for families of children with externalizing behaviors who are on the wait list for psychiatric assessment at BC Children's hospital.
- Conditions
- Aggression, Hyperactivity, Impulsive Behaviors
- Trial name
- NCT01483521
- Testing
- Clinical home visitation
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of British Columbia
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Impulsive Aggression
Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors
The purpose of this non-interventional study is to optimize the point subtraction aggression paradigms (PSAP) task in typically developing children (TDC).
- Trial name
- NCT03615703
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Anxiety Disorders and Symptoms Depressive Symptoms, Risk Factors (Rejection, Bullying/Cyberbullying, Addictions, Healthy Lifestyle Habits, Exam Stress Management, Ecoanxiety, Expressed Emotion)
Selective Prevention Transdiagnostic Intervention for At-risk Adolescents With Booster Sessions. (PROCARE+ 2.0)
Emotional disorders such as anxiety and depression are significantly underdiagnosed and undertreated, even though they are some of the most prevalent mental health conditions, especially among young individuals.
- Trial name
- NCT06185049
- Testing
- PROCARE+ (Core intervention with add-on modules) and two booster sessions., PROCARE+ (Core intervention with add-on modules) and one booster session, PROCARE+ (Core intervention with add-on modules) without booster sessions.
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- University of Jaén